An Overview of Daiichi Sankyo 's 395 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
Daiichi Sankyo Co., Ltd. is a pharmaceutical organization founded in 2005 and based in Tokyo, Japan. The company operates in the field of biomedicine and has a diverse portfolio of drugs targeting various therapeutic areas.
Daiichi Sankyo has a significant presence in the field of oncology, with 53 drugs developed for the treatment of neoplasms. This indicates a strong focus on cancer research and development. The company also has a substantial number of drugs in the areas of nervous system diseases, skin and musculoskeletal diseases, cardiovascular diseases, and respiratory diseases, with 46 drugs each.
Daiichi Sankyo's top target is dystrophin, with 5 drugs developed. Dystrophin is a protein involved in muscular dystrophy, suggesting that Daiichi Sankyo has a focus on developing treatments for this condition. Other frequently developed targets include ACE (angiotensin-converting enzyme), PBPs (penicillin-binding proteins), BRD4 (bromodomain-containing protein 4), sodium channels, bacterial top II, MLL1 + menin, KLK5 (kallikrein-related peptidase 5), CD276 (cluster of differentiation 276), and Phospho-N-acetylmuramoyl pentapeptide transferase. These targets indicate the company's efforts in developing drugs for various diseases and conditions, including cardiovascular diseases, bacterial infections, and cancer.
The pipeline consists of drugs in different phases of development. The company has 3 drugs in the discovery phase, indicating ongoing research and exploration of new treatment options. In the preclinical phase, there are 28 drugs, suggesting that Daiichi Sankyo is actively conducting preclinical studies to assess the safety and efficacy of potential drug candidates.
In the subsequent phases of clinical development, Daiichi Sankyo has 22 drugs in Phase 1, 21 drugs in Phase 2, and 7 drugs in Phase 3. These numbers indicate a robust clinical development pipeline, with multiple drugs progressing through different stages of clinical trials. Additionally, the company has 84 drugs approved, indicating a successful track record in bringing drugs to market.
In summary, Daiichi Sankyo Co., Ltd. is a pharmaceutical organization with a diverse portfolio of drugs targeting various therapeutic areas. The company has a strong focus on oncology, with a significant number of drugs developed for the treatment of neoplasms. Additionally, Daiichi Sankyo has a broad therapeutic approach, addressing diseases and conditions in areas such as nervous system diseases, cardiovascular diseases, respiratory diseases, and infectious diseases. The company's pipeline indicates ongoing research and development efforts, with drugs in different phases of clinical development. Overall, Daiichi Sankyo demonstrates a commitment to advancing biomedicine and addressing unmet medical needs.
